Table 1.
Patient characteristics.
| Total Study Participants (n) | 140 Patients |
|---|---|
| Gender | Male—110 patients (79%) |
| Female—30 patients (21%) | |
| Age years |
67.7 ± 8.9 |
| Patients with extrahepatic disease n |
7 (5%) |
| MELD score | 14.5 ± 5.81 |
| AFP ng/mL |
22,996.7 ± 130,814.5 |
| Total bilirubin mg/dL |
1.8 ± 2.1 |
| Total number of tumors n |
205 |
| Location of tumors per hepatic lobe n (%) |
Left hepatic lobe—82 (40%) |
| Right hepatic lobe—123 (60%) | |
| Location of tumors per hepatic segment n (%) |
Segment 1—1 (0.5%) |
| Segment 2—11 (5.4%) | |
| Segment 3—11 (5.4%) | |
| Segment 4a—19 (9.3%) | |
| Segment 4b—16 (7.8%) | |
| Segment 5—28 (13.7%) | |
| Segment 6—32 (15.6%) | |
| Segment 7—42 (20.5%) | |
| Segment 8—45 (21.9%) | |
| OPTN 5 tumors n (%) |
156 (76%) |
| Mean tumor size cm |
4.71 ± 3.6 |
MELD: Model For End-Stage Liver Disease; AFP: Alpha Fetoprotein; OPTN 5: Organ Procurement and Transplantation Network classification 5.